Allergan Aesthetics, an AbbVie company, has announced the approval of Boey® (trenibotulinumtoxinE) in Europe by the European Commission.
Boey® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved in Europe for the temporary improvement in the appearance of moderate to severe lines between the eyebrows seen at maximum frown (glabellar lines) in adult patients, when these have an important psychological impact.
In clinical studies, onset of effect was observed as early as eight hours after treatment and effects lasted two to three weeks. The EC decision applies across all 30 European Economic Area (EEA) countries and follows approval in Canada in June 2026.
Darin Messina, senior vice president and global head of aesthetics research and development at AbbVie, commented: “The EU approval of Boey® marks an important step forward for our development programme and builds on the momentum we’ve established with Health Canada’s approval earlier this year."
“This milestone reflects the scientific rigor behind Boey and reinforces our commitment to advancing innovative options as we work to bring this treatment to healthcare.”
